ALG8

Across TCGA pan-cancer cohorts, ALG8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ALG8 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALG8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ALG8 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where ALG8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.849	0.560	.005	27	view →
PDAC	DFS	Median	III,IV	0.321	0.971	.006	21	view →
CCRCC	OS	Median	All	0.583	1.000	.040	5	view →
LUAD	DFS	Quartile	All	0.996	0.828	.013	4	view →
LSCC	OS	Median	III,IV	0.901	0.484	.029	2	view →
UCEC	DFS	Median	All	0.785	0.923	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ALG8–HNSC (DFS)

Open the HNSC breakdown →